Work

Phase 3 trial of lorlatinib in treatment-naive patients (Pts) with ALK-positive advanced non–small cell lung cancer (NSCLC): Comprehensive plasma and tumor genomic analyses.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.9070

Authors: Alessandra Bearz, Jean-Francois Martini, Jacek Jassem, Sang-We Kim, Gee-Chen Chang, Alice Tsang Shaw, Deborah Shepard, Elisa Dall’O, Anna Polli, Holger C. Thurm, Gerard Zalcman, Rosario Garcia Campelo, Konstantin Penkov, Hidetoshi Hayashi, Benjamin J. Solomon

Institutions: Centro di Riferimento Oncologico, Pfizer (United States), Gdańsk Medical University, Asan Medical Center, University of Ulsan, Chung Shan Medical University Hospital, Massachusetts General Hospital, Hôpital Bichat-Claude-Bernard, Complexo Hospitalario Universitario A Coruña, Kindai University, Peter MacCallum Cancer Centre

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Pfizer

OpenAlex ID: W4281873496

Cites:

Cited by: 5

Related to: 10